EUVIMEDEUVIMED entdecken
Crossref

Rare Oral Mucosal Manifestations of Hydroxyurea Therapy in Chronic Myeloid Leukemia

Deena Mudawi

Haematology International Journal · 2017

DOI: 10.23880/hij-16000107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haematology International Journal, 2017. Verfasst von Deena Mudawi. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML), is myeloproliferative neoplasm, that accounts for 15-20% of all leukemia's in adults, resulting from reciprocal translocation between the long arms of chromosomes 9 and 22(Philadelphia chromosome), producing BCR-ABL oncogene fusion, which is currently targeted by tyrosine kinase inhibiters (TKIs), but still Hydroxyurea (HU) usedin chronic myeloid leukemia, its role as cytoreduction and as bridging therapy before starting tyrosine kinase inhibitors (TKI).There are several recognized side effects of hydroxyurea, such as cutaneous abnormalities and here we report rare mucous manifestations of hydroxyurea.

Zitieren

APA

Mudawi, D. (2017). Rare Oral Mucosal Manifestations of Hydroxyurea Therapy in Chronic Myeloid Leukemia. Haematology International Journal. https://doi.org/10.23880/hij-16000107

Vancouver

Mudawi D. Rare Oral Mucosal Manifestations of Hydroxyurea Therapy in Chronic Myeloid Leukemia. Haematology International Journal. 2017. doi:10.23880/hij-16000107

BibTeX
@article{Mudawi2017,
  author = {Mudawi, Deena},
  title = {Rare Oral Mucosal Manifestations of Hydroxyurea Therapy in Chronic Myeloid Leukemia},
  journal = {Haematology International Journal},
  year = {2017},
  doi = {10.23880/hij-16000107}
}
Kostenlos starten →